GE Showcases Breast Tomosynthesis Solution

November 28, 2014
Diagnostic Imaging Staff

GE will demonstrate at RSNA 2014 its newly FDA-approved tomosynthesis solution.

GE Healthcare will showcase at RSNA 2014 its new breast imaging 3D tomosynthesis solution, SenoClaire.

SenoClaire, which received FDA approval in August, uses a low-dose short X-ray sweep around the positioned breast with nine exposures acquired with a “step-and-shoot” method, which removes the potential from motion from the tube helping to preserve microcalcification sharpness and avoid image blur, GE said.

The SenoClaire has no increase in dose from a 2D standard mammogram to a 3D view, GE said.

[[{"type":"media","view_mode":"media_crop","fid":"29834","attributes":{"alt":"GE SenoClaire","class":"media-image media-image-right","id":"media_crop_954194364083","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"3114","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","style":"height: 240px; width: 300px; border-width: 0px; border-style: solid; margin: 1px; float: right;","title":"GE SenoClaire","typeof":"foaf:Image"}}]]